Expanded Access to RBS2418
Sponsor
Riboscience, LLC. (Industry)
Overall Status
Available
CT.gov ID
NCT05683470
Collaborator
Dr. Bertrand Tuan (Other)
Study Details
Study Description
Brief Summary
This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Given lack of any therapeutic options such as standard of care chemotherapy for this single patient owing to lack of tolerability and opportunity to enroll in any clinical trial due to extent of disease, patient desires to try compassionate use protocol with RBS2418, an oral immunotherapeutic agent that is currently in clinical trials and is well tolerated by patients. Furthermore, patient's tumor has been shown to express ENPP1, the protein targeted by RBS2418
Study Design
Study Type:
Expanded Access
Official Title:
Expanded Access to RBS2418 for an Individual Patient With Pancreatic Cancer
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
Female
Inclusion Criteria:
- The patient is willing and able to provide informed consent. Only the patient for whom this clinical study/experimental treatment was designed will be given the investigational drug under the treatment of the PI. No other patient is authorized to participate in or to receive treatment under this treatment protocol.
Exclusion Criteria:
- Not applicable
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Riboscience, LLC.
- Dr. Bertrand Tuan
Investigators
- Principal Investigator: Bertrand Tuan, MD, Pacific Hematology and Oncology Associates
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Riboscience, LLC.
ClinicalTrials.gov Identifier:
NCT05683470
Other Study ID Numbers:
- RBS2418-EA-002
First Posted:
Jan 13, 2023
Last Update Posted:
Jan 13, 2023
Last Verified:
Dec 1, 2022